Targeting miR-27 with Antisense Oligonucleotides for Disease Modification in Parkinson’s Disease
Objective: Achieve disease modification in idiopathic Parkinson’s Disease through miR-27 targeting using Antisense Oligonucleotides Background: There are currently no disease-modifying therapies for Parkinson’s Disease (PD).…Multiple N-of-1 trials to investigate hypoxia-based treatment in Parkinson’s disease: safety and short-term effects
Objective: In this study, we describe the safety and short-term effects of the first hypoxia-based treatment trial in Parkinson’s disease by deploying a personalized multiple…Integrated safety analysis of BIA-28-6156 phase 1 clinical trials (a novel allosteric activator of beta-glucocerebrosidase)
Objective: To describe the safety profile and tolerability of BIA-28-6156 observed during phase 1 clinical trials. Background: BIA-28-6156 is a novel allosteric activator of beta-glucocerebrosidase…Experiences of People with Parkinson’s Disease use of a wearable technology for the management of drooling; qualitative insights from the Cue Band study
Objective: In the Cue Band study, people with Parkinson’s Disease (PwP) are participating in a randomised controlled trial to compare a mobile Application (App) with…Use of a wearable vibration-based device for the treatment of Parkinson’s disease tremor
Objective: To assess the use of a wearable vibration-based device for the treatment of Parkinson’s disease (PD) tremor. Background: PD is a neurodegenerative movement disorder…Glunomab: a novel therapeutics for the treatment of Parkinson’s Disease
Objective: The focus of this study was: 1) to characterize the expression and the localization of an endogenous protease, tissue plasminogen activator (tPA) in the…Results from IRL790C005 – A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study Evaluating the Efficacy of Mesdopetam on Daily On-Time without Troublesome Dyskinesia in Patients with Parkinson’s Disease
Objective: The objective of the Phase 2b-trial was to investigate efficacy and safety of three doses of Mesdopetam as adjunct treatment in patients with PD…Observations on 5 Parkinson’s patients taking Mucuna pruriens as natural source of levodopa
Objective: To explore potential benefits and tolerability of extracts from Mucuna pruriens for dopaminergic treatment of Parkinson’s patients. Background: Capsules containing freeze-dried, aqueous extract from…Protective potential of laughter yoga and clapping exercise on stress level and motor functions in Parkinson’s disease patients with type 2 diabetes
Objective: To examine the protective potential of laughter yoga and clapping exercise on blood glucose regulation on stress level and motor functions of PD patients…LRRK2 PROTAC® degrader molecules induce robust biomarker responses in preclinical in vivo pharmacology studies following acute and chronic oral dosing
Objective: Report on the non-clinical in vivo pharmacokinetic and pharmacodynamic biomarker response to PROteolysis TArgeting Chimera (PROTAC®) molecules designed to induce degradation of leucine rich…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 12
- Next Page »